| You are here: Home: BCU Surgeons Vol.2 Issue 4: Aman Buzdar, MD, FACP: Select publications
Select publications
Publications discussed by Dr Buzdar
Buzdar AU et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95(9):2006-16. Abstract
Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 2002:Abstract 12.
Sainsbury R on behalf of the ATAC Trialists' Group. Beneficial side-effect profile of anastrozole compared with tamoxifen confirmed by additional 7 months of exposure data: A safety update from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. San Antonio Breast Cancer Symposium 2002:Poster 633. Abstract
Use of bisphosphonates in breast cancer
Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer2002;10(5):399-407. Abstract
Brown JE, Coleman RE. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 2002;4(1):24-9. Abstract
Chlebowski RT. Factors influencing the role of bisphosphonates in breast cancer management. Semin Oncol 2001;28(4 Suppl 11):42-8. Abstract
Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of randomized phase III trials. Am J Clin Oncol 2002;25(6 Suppl 1):S25-31. Abstract
Gasser JA et al. Intravenous administration of zoledronic acid offers long-term protection against bone loss in rats induced as a consequence of estrogen deprivation. Breast Cancer Res Treat 2002:Abstract 274.
Gralow JR. The role of bisphosphonates as adjuvant therapy for breast cancer. Curr Oncol Rep 2001;3(6):506-15. Abstract
Paterson AH. Bisphosphonates: Biological response modifiers in breast cancer. Clin Breast Cancer 2002;3(3):206-16; discussion 217-8. Abstract
Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002;(1):CD003474. Abstract
Pickering LM et al. The bisphosphonate zoledronic acid downregulates signalling through Ras effector pathways in human breast cancer cell lines. Breast Cancer Res Treat 2002:Abstract 356.
Pickering LM, Mansi JL. The role of bisphosphonates in breast cancer management: Review article. Curr Med Res Opin 2002;18(5):284-95. Abstract
Plunkett TA, Rubens RD. Bisphosphonate therapy for patients with breast carcinoma. Cancer 2003;97(3 Suppl):854-8. Abstract
Reinholz GG et al. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: Identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat 2002;71(3):257-68. Abstract
Saarto T et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001;20;84(8):1047-51. Abstract
Senaratne SG, Colston KW. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002;4(1):18-23. Abstract
Theriault RL, Hortobagyi GN. The evolving role of bisphosphonates. Semin Oncol 2001;28(3):284-90. Abstract
Van Poznak C. How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol 2001;28(4 Suppl 11):69-74. Abstract
Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control 2002;9(6):480-9. Abstract
Vehmanen et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37(18):2373-8. Abstract
|
